Protocol Status: PUBLISHED
Protocol:
Version: 2026.01
Effective Date:
Last Reviewed:
Medical Director Approval:
Clinical Note: This content reflects current GCEMS clinical guidelines as of the dates listed above. If content appears inconsistent with current policy, use the most recent approved guideline and notify leadership for correction.

Vecuronium Bromide

(Norcuron)

 

GCEMS Protocol:

 

  • Post Airway Management

 

Indications:

 

  • Continued agitation after post airway sedation

 

Contraindications:

 

  • Known hypersensitivity

 

Side Effects:

 

  • Prolonged paralysis, hypotension, bradycardia

 

Adult:

 

  • 0.1 mg/kg; Max 10 mg IV/IO

 

Pediatric:

 

  • Not Approved